Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Journal of Clinical Oncology,
Год журнала:
2024,
Номер
42(15), С. 1830 - 1850
Опубликована: Март 19, 2024
To
update
an
evidence-based
guideline
to
assist
in
clinical
decision-making
for
patients
with
advanced
hepatocellular
carcinoma
(HCC).
Язык: Английский
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Cytokine & Growth Factor Reviews,
Год журнала:
2024,
Номер
79, С. 29 - 38
Опубликована: Авг. 24, 2024
Язык: Английский
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Current Issues in Molecular Biology,
Год журнала:
2024,
Номер
46(6), С. 5965 - 5983
Опубликована: Июнь 13, 2024
Hepatocellular
carcinoma
(HCC)
represents
a
significant
burden
on
global
healthcare
systems
due
to
its
considerable
incidence
and
mortality
rates.
Recent
trends
indicate
an
increase
in
the
worldwide
of
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
shift
etiology
HCC,
with
MASLD
replacing
hepatitis
B
virus
as
primary
contributor
new
cases
HCC.
MASLD-related
HCC
exhibits
distinct
characteristics
compared
viral
including
unique
immune
cell
profiles
resulting
overall
more
immunosuppressive
or
exhausted
tumor
microenvironment.
Furthermore,
is
frequently
identified
older
age
groups
among
individuals
cardiometabolic
comorbidities.
Additionally,
greater
percentage
occur
noncirrhotic
patients
those
etiologies,
hindering
early
detection.
However,
current
clinical
practice
guidelines
lack
specific
recommendations
for
screening
patients.
The
evolving
landscape
management
offers
spectrum
therapeutic
options,
ranging
from
surgical
interventions
locoregional
therapies
systemic
treatments,
across
various
stages
disease.
Despite
ongoing
debates,
evidence
does
not
support
differences
optimal
treatment
modalities
based
etiology.
In
this
study,
we
aimed
provide
comprehensive
overview
literature
trends,
characteristics,
implications,
Язык: Английский
Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Фев. 19, 2025
Abstract
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
common
solid
malignancies
in
world.
Due
to
limited
effectiveness
current
drug
treatments,
further
research
on
HCC
necessary.
PANoptosis
defined
as
an
inflammatory
RCD
whose
main
features
combine
pyroptosis,
apoptosis
and
necroptosis
which
cannot
be
explained
by
any
these
three
RCDs
alone.
In
HCC,
risk
stratification
based
PANoptosis-associated
lncRNAs
has
clinical
application
potential.
this
study,
we
explored
related
PANoptosis-related
(PRLs)
analyzing
significantly
differentially
expressed
genes
HCC.
HCC-associated
PRL
scores
were
established
WGCNA,
LASSO
analysis
multivariate
Cox
assessment.
Subsequently,
verified
prognostic
ability
score
for
patients,
basis
a
assessment
model
its
reliability.
The
relationship
between
immune
infiltration
well
sensitivity
was
analyzed
evaluate
reference
value
model.
Western
blot
PCR
reliability
bioinformatics
results.
observed
suppression
progression
invasiveness
following
selected
knockdown
validated
our
Our
results
provide
new
evidence
role
Язык: Английский
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
Discover Oncology,
Год журнала:
2024,
Номер
15(1)
Опубликована: Июль 3, 2024
Abstract
Liver
cancer
is
the
sixth
most
commonly
diagnosed
and
third
leading
cause
of
death
in
world,
hepatocellular
carcinoma
(HCC)
common
form
liver
cancer.
More
than
half
HCC
patients
are
at
an
advanced
stage
often
require
systemic
therapy.
Dysregulation
activity
receptor
tyrosine
kinases
(RTKs)
involved
development
progress
HCC,
RTKs
therefore
potential
targets
for
therapy
(aHCC).
Currently,
a
total
six
small
molecule
kinase
inhibitors
(TKIs)
have
been
approved
aHCC,
including
first-line
sorafenib,
lenvatinib,
donafenib,
second-line
regorafenib,
cabozantinib,
apatinib.
These
TKIs
improved
survival,
which
associated
with
disease
stage,
etiology,
function,
tumor
burden,
baseline
levels
alpha-fetoprotein,
treatment
history.
This
review
focuses
on
clinical
outcomes
these
key
trials,
retrospective
real-world
studies
discusses
future
perspectives
aim
to
provide
up-to-date
evidence
decision-making
aHCC.
Язык: Английский
Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma
Frontiers in Medicine,
Год журнала:
2023,
Номер
10
Опубликована: Ноя. 13, 2023
EDITORIAL
article
Front.
Med.,
13
November
2023Sec.
Gastroenterology
Volume
10
-
2023
|
https://doi.org/10.3389/fmed.2023.1325304
Язык: Английский